BioCentury | Oct 28, 2019

Prolactin inhibition could treat MS

...disease INDICATION: Multiple sclerosis (MS) Inhibition of PRL or ZBTB20, a transcription factor that promotes PRL...
...treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CSF levels of PRL...
...higher in late-stage disease than early-stage disease. Also in the model, Parlodel bromocriptine, which blocks PRL...
BioCentury | Jun 14, 2019
Preclinical News

June 13 Preclinical Quick Takes: A*STAR's mAb against tumor-displayed antigen; plus Columbia, Genentech and more

A*STAR targets externalized antigen to kill tumor cells The Agency for Science Technology and Research has licensed PTP4A3-targeting cancer therapy PRL3-zumab to spinout company Intra-Immu SG Pte Ltd. (Singapore). A*STAR and colleagues reported in a...
BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

...hormone PRL are associated with the disease. According to HopeMed, undisclosed data from Bayer suggest PRL-PRLR...
...1158061 for other chronic diseases with dysregulated PRL signaling. The company isn’t disclosing indications, but PRL...
...Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 AbbVie Inc. Bayer AG Hope Medicine Inc. Oncolix Inc. Peking University Xoma Corp. 5-alpha reductase GnRH/LHRH receptor Prolactin (PRL) Prolactin...
BioCentury | Apr 19, 2019
Finance

Hope for China’s academic spinouts

...years." In its deal with Bayer, Hope gained a global license to BAY 1158061. The anti-prolactin...
...Ltd. I-Mab Biopharma Innovative Cellular Therapeutics Co. Ltd. Peking University Pfizer Inc. Roche Suzhou Ribo Life Science Co. Ltd. Zai Lab Ltd. Zhejiang University Prolactin...
BioCentury | Apr 11, 2019
Company News

Hope Medicine in-licenses Bayer’s BAY 1158061

...to treat male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL...
...Hope's series A. Targets: PRL - Prolactin; PRLR - Prolactin receptor Hongjiang Li, Staff Writer BAY 1158061 Bayer AG Prolactin (PRL) Prolactin...
BioCentury | Apr 10, 2019
Financial News

Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

...treat male and female pattern hair loss, endometriosis and other chronic diseases associated with dysregulated PRL...
...ENPP1 - ectonucleotide pyrophosphatase/phosphodiesterase 1; PRLR - Prolactin receptor BioCentury Staff INZ-701 Cullgen Inc. Inozyme Pharma Inc. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Prolactin...
BioCentury | Nov 18, 2016
Emerging Company Profile

Suppressing somatostatin

...in Diabetes in 2013 by researchers at the University of Toronto and colleagues showed that PRL-2903...
...insulin overdose. Zucara hopes to replicate the findings over the next year with analogs of PRL-2903...
...Centre for Drug Research and Development (CDRD). The company also has exclusive worldwide rights to PRL-2903...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Protein tyrosine phosphatase type IVA 1 (PTP4A1; PRL1)

Cancer INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibition of PTP4A1 could help treat melanoma. In patient tumor samples, levels of PTP4A1 were higher than in healthy skin samples, and the high...
BioCentury | Jul 25, 2016
Clinical News

XOMA 213: Phase II started

...IgG1 kappa mAb against prolactin receptor (PRLR) Indication: Suppress lactation immediately postpartum Endpoint: Reduction in prolactin...
BioCentury | Sep 17, 2015
Top Story

Phase III schizophrenia data lift Intra-Cellular to record high

...Both doses of ITI-007 showed no significant difference from placebo on weight gain, metabolic parameters, prolactin...
Items per page:
1 - 10 of 66